KQ Labs’ Post

This is an insightful and timely article. According to a recent analysis published by Cruchbase, based on data through May 2024, the amount of capital raised through Series A funding for biotechs is expected to rise above last year's total, but fewer companies are actually receiving the investments. The projected # of biotechs receiving Series A for FY2024 is projected to be ~20% lower than 2023 and ~40% lower than 2019 / 2020. With fewer companies receiving larger amounts of capital, there is a significant funding gap and a tremendous opportunity for organizations, like Blackbird Laboratories and the others mentioned in this article, to identify promising research, leverage their technical expertise to de-risk early development pitfalls and to accelerate the development of novel and valuable medicines. #Innovation #Entrepreneurship #Biotech

We were accepted to the Life Science Accelerator last week.  Bodo Brückner and Markus Bühler, thank you for this! We will work on the improvements for our new service platform — 'Second Opinion Oncology'! It will allow cancer patients worldwide to get consultations from competent Western doctors more smoothly, easily, and affordably. → Improve our business model, pricing, and growth strategy.  → Network with the stakeholders in the medical industry and investors. → Mentors will help in creating our new venture. Last week, we had a Pitch workshop (part 1) with Colin Bennett. He drew attention to important points in pitching and helped to look at our pitch from a different angle. Thanks, Colin! I liked the metaphor of an elephant and rider: The elephant is the emotional brain, and the rider is the logical one. It is a difficult job to control an elephant. It's too big. So, we should consider satisfying the 'elephant' of our listeners. Attract their attention, make them believe, and show care for them. We are eagerly looking forward to the next part of the pitch workshop and the exciting journey ahead with Life Science Accelerator! P.S. More about the Accelerator: https://lnkd.in/e6w4S-gC

I agree with Grace Cordovano, PhD, BCPA. It is GREAT, and I am excited, to see the inaugural CancerX Moonshot Accelerator having this impact during a period where capital has disapeared for most of the #disruptive #Immunooncology #biotechs. But make no mistake, there are many treatments that have shown substantial benefit to #patients with #cancer that can’t find funding. The acceptance rate for #moonshot should be closer to 20%. Not 12%!!! Many of the high risk/high reward ideas don’t even fit the moonshot metrics and are not being evaluated, let alone funded. This is something that should be fixed. As a related side note: Grateful to Society for Immunotherapy of Cancer (SITC) for working to educate and bring #investors back to the #immunooncology space which has enormous potential and promise to increase not just response rates, but also CURE rates for patients with cancer. There is a goal of having 100 new immunooncology drugs approved by FDA IN THE NEXT DECADE. The clock is ticking! National Cancer Institute (NCI), Incyte AstraZeneca Novartis Roche Bayer Bristol Myers Squibb, Pfizer , Moderna , UbiVac , Absci EMD Serono, Inc., Agenus , Regeneron Inhibrx Biosciences, Inc. Iovance Biotherapeutics, Inc. Oregon Bioscience Association Nike Intel Corporation Twist Bioscience Columbia Sportswear Company https://lnkd.in/gF2TBtwF

Are you a current or past American Cancer Society grantee? #DYK We’ve supported approximately 24,000 researchers across more than 1,400 institutions, helping to bring many new treatments, diagnostics, and interventions from the bench to the bedside. However, for every innovation that ACS-funded researchers have brought to market, countless others have fallen into the so-called “Valley of Death”, the gap between when basic research funding ends but investors are not yet ready to accept the risk of investing in the new technology or startup. Through the newly launched Collaborative Learning Community (CLC), the ACS Extramural Discovery Science team, together with the American Cancer Society’s venture capital arm BrightEdge, are helping researchers tackle this challenge head on by providing entrepreneurship-focused programming for scientists that have received grant funding from ACS. Interested researchers can access the CLC Virtual Platform by visiting BrightEdge Entrepreneurs Program and clicking "Enter Here" to create a new user profile: https://lnkd.in/gsWpEtCu. There is no cost to access this platform, which is available to all past and present ACS grantees. For questions about this program or other innovation programming, please contact BrightEdge.Innovation@cancer.org

We are excited to announce our first ever #EAAMOSocialHackathon as part of the ACM Conference on Equity and Access in Algorithms, Mechanisms, and Optimization (EAAMO) 🌟   This event is organized in collaboration with the Universidad Autónoma de San Luis Potosí and IPICyT.   💡 𝐖𝐡𝐚𝐭 𝐢𝐬 𝐭𝐡𝐞 𝐒𝐨𝐜𝐢𝐚𝐥 𝐇𝐚𝐜𝐤𝐚𝐭𝐡𝐨𝐧? This event is a unique opportunity to address critical social issues through innovative technological solutions. Local partners will provide curated datasets and extensive context to inform participants’ solutions, ensuring they incorporate insights from impacted communities and policymakers. 📅 𝐈𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐃𝐚𝐭𝐞𝐬: • August: Kickoff at Virtual Colloquium (August 22, 2024) & dataset release • September: Project development & submissions • October: Finalists & pitches at ACM EAAMO '24 • November onwards: Collaboration with policymakers ➡ 𝐖𝐡𝐲 𝐩𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞? • By submitting a proposal, you and your team members get free virtual registration to attend EAAMO’24 • Finalists get one travel grant per team to attend EAAMO’24 in person • The winning team gets a monetary prize as well as the opportunity to collaborate directly with local policymakers to implement their solution 💡 𝐓𝐡𝐢𝐬 𝐘𝐞𝐚𝐫’𝐬 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞: 𝐓𝐚𝐜𝐤𝐥𝐢𝐧𝐠 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐢𝐧 𝐌𝐞𝐱𝐢𝐜𝐨 This event will focus on addressing breast cancer disparities in Mexico through innovative technological solutions. Join us to make a real impact by leveraging the power of algorithms, optimization, and mechanism design. 𝐑𝐞𝐚𝐝𝐲 𝐭𝐨 𝐦𝐚𝐤𝐞 𝐚 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞? 𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐭𝐨 𝐠𝐞𝐭 𝐬𝐭𝐚𝐫𝐭𝐞𝐝! 🔗 https://lnkd.in/gy8bAWYu 

"Unlocking implementation science" ✨Today, I gained valuable insights at the Children's Cancer Hospital Foundation 57357 webinar led by Dr. Maysam Homsi, DrPH, MPH, CCRP ✨I discovered the power of implementation science in bridging the gap between research and real-world practice. Learning about frameworks, strategies, and real-world applications has opened new perspectives on how to effectively translate research into actionable solutions. Excited to explore this field further!

🌟 Exciting Update from the LUCIA EU Project Advisory Board Meeting! 🌟   Our recent meeting with the LUCIA Project Advisory Board was a productive session filled with insightful discussions and valuable contributions towards our project objectives. Here's a brief overview of what took place:   💡 Updates on the First Year of LUCIA: Yoav Broza from Technion - Israel Institute of Technology presented comprehensive updates on the progress made during the project's first year together with Hossam Haick. Engaging questions and comments from all members enriched our understanding and provided valuable perspectives. 🗣 Stakeholder Contact List Input: We sought input on our stakeholder contact list, organisations and projects not to miss in the field of (lung) cancer, ensuring inclusivity and breadth in our outreach efforts. 💬 Discussion on the first LUCIA Social Lab Workshop Concept: A dynamic discussion led by our Ivett and Emad explored the concept for our upcoming Social Lab workshop. We discussed barriers to the implementation of LUCIA technologies to real-life settings to include in our discussions with representatives of (lung) cancer organisations and EU-level initiatives. 🙏 Thank you to all our Advisory Board members for your invaluable guidance and contributions @Johanna Mattson @Kwun Fong Mehdi Snene, Ph.D.. Together, we're advancing towards understanding lung cancer-related risk factors and their impact! #LUCIAProject #AdvisoryBoardMeeting #Collaboration #Innovation

Your ticket to a world of innovation awaits! From sustainable interiors to AI-driven cancer diagnosis tools, meet 10 startups reshaping industries and moving change. This way to get inspired by their incredible stories filled with challenges and wins, in our latest article👇 https://lnkd.in/eWC8p94Z

"There are as many patients as there are mysteries. Each of them is a mystery. So it's like a research project, not with just one question, but with 1,000 questions. The immensity of the challenge is really great." Remy Nicolle, Cure51 Co-founder and Senior Scientific Advisor 🔗 Watch the full interview on our page. #GlobalResearch #CancerInnovation #RemyNicoll #CURE51 #CollaborativeScience #OncologyInsights

Check out our most recent blog! #MicrobiomeResearch #CancerResearch